Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03232918 · ClinicalTrials.gov registry record · Phase 4

Oxytocin and Fetal Heart Rate Changes

A Phase 4 study of Fetal Bradycardia Complicating Labor and Delivery and Fetal Bradycardia During Labor, sponsored by Unyime Ituk.

Recruiting
Registry status
Phase 4
Development phase
730
Enrollment target
2
Study locations

NCT03232918 is a Phase 4 study of Fetal Bradycardia Complicating Labor and Delivery and Fetal Bradycardia During Labor that is actively recruiting participants, run by Unyime Ituk. The registered enrollment target is 730 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03232918, a Phase 4 study of Fetal Bradycardia Complicating Labor and Delivery and Fetal Bradycardia During Labor, is actively recruiting participants, sponsored by Unyime Ituk.

RECRUITING
Registry status
Phase 4
Development phase
730 participants
Enrollment target
2
Study locations

Study Summary

The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. The study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to initiation of combined spinal epidural analgesia will cause a reduction in the incidence of adverse fetal heart rate changes.

Interventions

  • DRUG Half dose Oxytocin

Study Locations (2)

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 730 participants
Start Date 2019-02-20
Est. Completion 2025-12-31
Phase Phase 4

Sponsor

Unyime Ituk

1 total trials

What the Registry Record Tells You About NCT03232918

The ClinicalTrials.gov registry entry for NCT03232918 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unyime Ituk, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Fetal Bradycardia Complicating Labor and Delivery appearing as the primary indexed condition, and to 1 intervention - of which Half dose Oxytocin is the first listed.

NCT03232918 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Iowa, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03232918 about?

NCT03232918 is a clinical study titled "Oxytocin and Fetal Heart Rate Changes". The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. The study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to ini...

What is the current status of trial NCT03232918?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 730 participants. The study started on 2019-02-20. Estimated completion is 2025-12-31.

What conditions does trial NCT03232918 study?

This clinical trial studies the following conditions: Fetal Bradycardia Complicating Labor and Delivery, Fetal Bradycardia During Labor, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus.

What interventions are being tested in trial NCT03232918?

The interventions under investigation include: Half dose Oxytocin (DRUG).

Who is sponsoring clinical trial NCT03232918?

This trial is sponsored by Unyime Ituk, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03232918 being conducted?

This trial has 2 study locations across Iowa, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.